PL3019185T3 - Leczenie skojarzone atopowego zapalenia skóry - Google Patents

Leczenie skojarzone atopowego zapalenia skóry

Info

Publication number
PL3019185T3
PL3019185T3 PL14747994T PL14747994T PL3019185T3 PL 3019185 T3 PL3019185 T3 PL 3019185T3 PL 14747994 T PL14747994 T PL 14747994T PL 14747994 T PL14747994 T PL 14747994T PL 3019185 T3 PL3019185 T3 PL 3019185T3
Authority
PL
Poland
Prior art keywords
treatment
combined
atopic dermatitis
atopic
dermatitis
Prior art date
Application number
PL14747994T
Other languages
English (en)
Inventor
Mark Leonard OFFERHAUS
Fritz Eichenseher
Original Assignee
Micreos Human Health B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48748062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3019185(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Micreos Human Health B.V. filed Critical Micreos Human Health B.V.
Publication of PL3019185T3 publication Critical patent/PL3019185T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/217IFN-gamma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017Lysozyme (3.2.1.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL14747994T 2013-07-11 2014-07-10 Leczenie skojarzone atopowego zapalenia skóry PL3019185T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13176034 2013-07-11
PCT/NL2014/050470 WO2015005787A1 (en) 2013-07-11 2014-07-10 Combination treatment for atopic dermatitis
EP14747994.3A EP3019185B1 (en) 2013-07-11 2014-07-10 Combination treatment for atopic dermatitis

Publications (1)

Publication Number Publication Date
PL3019185T3 true PL3019185T3 (pl) 2021-08-02

Family

ID=48748062

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14747994T PL3019185T3 (pl) 2013-07-11 2014-07-10 Leczenie skojarzone atopowego zapalenia skóry

Country Status (11)

Country Link
US (2) US10357547B2 (pl)
EP (2) EP3789033A1 (pl)
KR (2) KR102409340B1 (pl)
CN (1) CN105517563A (pl)
AU (1) AU2014287845B2 (pl)
DK (1) DK3019185T3 (pl)
ES (1) ES2853327T3 (pl)
IL (1) IL243570B (pl)
PL (1) PL3019185T3 (pl)
SG (2) SG11201600180WA (pl)
WO (1) WO2015005787A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201692031A1 (ru) 2014-04-08 2017-07-31 Лисандо Аг Фармацевтическая композиция с активным действием в отношении хронических бактериальных инфекций
PL3144387T3 (pl) 2015-09-15 2018-06-29 Micreos Human Health B.V. Nowy polipeptyd endolizyny
EP3464583A1 (en) 2016-05-27 2019-04-10 Sasinapas Co., Ltd. Endolysin variant
CA3039561A1 (en) 2016-10-07 2018-04-12 Micreos Human Health B.V. Vasoconstrictive and antibacterial combination treatment for rosacea
MX2020011016A (es) * 2018-04-18 2021-01-29 Forte Subsidiary Inc Composiciones para el tratamiento de condiciones de la piel.
AU2019276253A1 (en) 2018-05-30 2020-11-26 Lysando Ag Novel antimicrobial proteins
BR112022018599A2 (pt) 2020-03-19 2022-12-20 Micreos Human Health Bv Uma proteína de interesse estabilizada
EP4138883B1 (en) * 2020-04-20 2025-09-10 Micreos Human Health B.V. A chimeric endolysin polypeptide
WO2022195108A2 (en) 2021-03-19 2022-09-22 Eligo Bioscience Cosmetic use of engineered postbiotics comprising bacteriocins and/or endolysins
WO2022195109A1 (en) 2021-03-19 2022-09-22 Eligo Bioscience Therapeutic use of engineered postbiotics comprising bacteriocins and/or endolysins
WO2025093666A1 (en) 2023-11-01 2025-05-08 University Of Copenhagen Treatment of lymphoma
WO2026052743A1 (en) 2024-09-04 2026-03-12 Micreos Human Health B.V. Reduction of trans-epidermal water loss by a polypeptide with antibacterial properties

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428784B1 (en) * 1997-10-31 2002-08-06 New Horizons Diagnostics Corp Vaginal suppository for treating group B Streptococcus infection
KR100910961B1 (ko) 2007-09-13 2009-08-05 주식회사 인트론바이오테크놀로지 황색포도상구균의 균막 처치에 효과적인 박테리오파지 또는그것 유래의 용균단백질
FR2954140A1 (fr) * 2009-12-17 2011-06-24 Oreal Compositions cosmetiques ou dermatologiques a base de bacteriocines et de prebiotiques
EP2338916A1 (en) * 2009-12-23 2011-06-29 Hyglos Invest GmbH Chimeric polypeptides and their use in bacterial decoloniation
ES2589784T5 (es) * 2011-05-04 2020-04-21 Micreos Human Health Bv Polipéptido

Also Published As

Publication number Publication date
IL243570A0 (en) 2016-03-31
WO2015005787A1 (en) 2015-01-15
CN105517563A (zh) 2016-04-20
IL243570B (en) 2020-04-30
KR20160032725A (ko) 2016-03-24
US20160151463A1 (en) 2016-06-02
KR102409340B1 (ko) 2022-06-22
ES2853327T3 (es) 2021-09-15
DK3019185T3 (da) 2021-02-15
EP3789033A1 (en) 2021-03-10
SG10202009810YA (en) 2020-11-27
EP3019185A1 (en) 2016-05-18
SG11201600180WA (en) 2016-02-26
AU2014287845B2 (en) 2019-11-14
US20260069666A1 (en) 2026-03-12
KR20220031725A (ko) 2022-03-11
CA2917726A1 (en) 2015-01-15
US10357547B2 (en) 2019-07-23
EP3019185B1 (en) 2020-11-18
AU2014287845A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
IL287516A (en) Medicinal uses of empagliflozin
LT2885010T (lt) Tautopatijos gydymo būdai
EP2968208A4 (en) TREATMENT OF CATAPLEXIA
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
PL3019185T3 (pl) Leczenie skojarzone atopowego zapalenia skóry
IL241101A0 (en) Medicinal uses of empagliflozin
LT3007726T (lt) Tautopatijos gydymo būdai
PT3626270T (pt) Tratamento de doenças cardiovasculares
PT2953948T (pt) Antagonistas de integrina fluorada
LT2981271T (lt) Empagliflozino terapinis panaudojimas
EP2945942A4 (en) Voriconazole IMMUNOASSAY
EP2996772A4 (en) Methods for the treatment of neurodegeneration
IL241096B (en) Treatment methods
DK3041506T3 (da) Behandlingsfremgangsmåde
HRP20181181T1 (hr) Postupak obrade i liječenja lišmenioze uporabom feksinidazola
TH1601000069A (th) การรักษาร่วมสำหรับโรคผื่นภูมิแพ้ผิวหนัง
GB201306411D0 (en) Treatment of inflammatory conditions
TH148799B (th) การบำบัดวัสดุที่ประกอบด้วยแมงกานีส
ES1098808Y (es) Juguete-instrumento de muneco bailarin
HRP20190035T1 (hr) Obrada krutina s visokim sadržajem sumpora
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment
UA28711S (uk) Масажер